Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
World Journal of Urology
Erschienen in: World Journal of Urology 3/2005

01.07.2005 | Topic Paper

Chemotherapy in metastatic renal cell cancer

verfasst von: Wolfgang Lilleby, Sophie D. Fosså

Erschienen in: World Journal of Urology | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

Currently, there is no standard treatment for patients with advanced renal cell carcinoma (RCC) who do not respond to or progress after transient remission to first-line immunotherapy. At the end of the 1990s, no single chemotherapeutic drug, alone or in combination with interleukin-2 (IL-2) or interferon-alfa (IFN), had shown activity beyond the one expected by immunotherapy alone. New drugs on the market such as the pyrimidine analog gemcitabine or taxane-based chemotherapeutics may show promising tumor activity in combination with targeted therapy, but this has to be substantiated in upcoming trials. There is a great need to develop effective systemic therapy for advanced MRCC and to evaluate the efficacy of new drugs in clinical trials.
Literatur
1.
Motzer RJ, Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163:408–417PubMed
2.
Mickisch G, Bier,H, Bergler W, et al. (1999) P-170 glycoprotein, glutathione and associated enzymes in relation to chemoresistance of primary human renal cell carcinomas. Urol Int 45:170–176
3.
Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162PubMed
4.
Mickisch GH (1994) Chemoresistance of renal cell carcinoma: 1986–1994. World J Urol 12:214–223
5.
Ford JM, Yang JM, Hait WN (1996) P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. Cancer Treat Res 87:3–38PubMed
6.
Anderson ME (1998) Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact 111/112:1–14
7.
Mickisch GH, Noordzij MA, Van der Gaast A et al. (1995) Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma. J Cancer Res Clin Oncol 121 [Suppl 3]:R11–16
8.
Braybrooke JP, Vallis KA, Houlbrook S et al. (2000) Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine. Cancer Chemother Pharmacol 46:27–34PubMed
9.
Gnarra JR, Tory K, Weng Y et al. (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85–90
10.
Bindra RS, Vasselli JR, Stearman R et al. (2002) VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 62:3014–3019PubMed
11.
Huang LE, Gu J, Schau M et al. (1998) Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 95:7987–7992PubMed
12.
Hockel M, Vaupel P (2001) Biological consequences of tumor hypoxia. Semin Oncol 28:36–41
13.
Fossa SD, Kramar A, Droz JP (1994) Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 30A:1310–1314PubMed
14.
Thiesse P, Ollivier L, Di Stefano-Louineau D et al. (1997) Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Francais d’Immunotherapie of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 15:3507–3514PubMed
15.
Erasmus JJ, Gladish GW, Broemeling L et al. (2003) Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 21:2574–2582
16.
Duffaud F, Therasse P (2000) New guidelines to evaluate the response to treatment in solid tumors (in French). Bull Cancer 87:881–886PubMed
17.
Therasse P (2002) Measuring the clinical response. What does it mean? Eur J Cancer 38:1817–1823PubMed
18.
Hrushesky WJ, Von Roemeling R, Lanning RM et al. (1990) Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol 8:1504–1513
19.
Yagoda A, Abi-Rached B, Petrylak D (1995) Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 22:42–60
20.
Fossa SD, Droz JP, Pavone-Macaluso MM et al. (1992) Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group. Eur J Cancer 28A:878–880PubMed
21.
Marcus SG, Choyke PL, Reiter R et al. (1993) Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 150:463–466PubMed
22.
Ryan CW, Vogelzang NJ, Stadler WM (2002) A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. Cancer 94:2602–2609PubMed
23.
Stadler WM, Huo D, George C et al. (2003) Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 170:1141–1145PubMed
24.
Bennouna J, Delva R, Gomez F et al. (2003) A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma. Oncology 64:25–27PubMed
25.
Haas NB, Giantonio BJ, Litwin S et al. (2003) Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network. Cancer 98:1837–1841PubMed
26.
Oevermann K, Buer J, Hoffmann R et al. (2000) Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 83:583–587PubMed
27.
Fizazi K, Rolland F, Chevreau C et al. (2003) A phase II study of irinotecan in patients with advanced renal cell carcinoma. Cancer 98:61–65PubMed
28.
Stadler WM, Kuzel T, Roth B et al. (1997) Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394–3398PubMed
29.
De Mulder PH, Weissbach L, Jakse G et al. (1996) Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 37:491–495PubMed
30.
Porta C, Zimatore M, Imarisio I, et al. (2004) Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study. Cancer 100:2132–2138PubMed
31.
Rini BI, Vogelzang NJ, Dumas MC et al. (2000) Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 18:2419–2426
32.
Escudier B, Chevreau C, Lasset C et al. (1999) Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d’Immunotherape. J Clin Oncol 17:2039–2043PubMed
33.
Bruntsch U, Heinrich B, Kaye SB et al. (1994) Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group. Eur J Cancer 30A:1064–1067PubMed
34.
Park DK, Ryan CW, Dolan ME et al. (2002) A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. Cancer Chemother Pharmacol 50:160–162PubMed
35.
Townsley CA, Chi K, Ernst DS et al. (2003) Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group, J Clin Oncol 21:1524–1529
36.
Berg WJ, Schwartz L, Yu R et al. (2001) Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma. Invest New Drugs 19:317–320CrossRefPubMed
37.
Yang JC, Sherry RM, Steinberg SM et al. (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127–3132CrossRefPubMed
38.
Atzpodien J, Kirchner H, Siebels M et al. (2004) Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22:1188–1194CrossRefPubMed
39.
Bleumer I, Oosterwijk E, De Mulder P et al. (2003) Immunotherapy for renal cell carcinoma. Eur Urol 44:65–75PubMed
40.
Fossa SD, Mickisch GH, De Mulder PH et al. (2004) Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. Cancer 101:533–540PubMed
41.
Motzer RJ, Murphy BA, Bacik J et al. (2000) Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18:2972–2980
42.
Sunkara U, Walczak JR, Summerson L et al. (2004) A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma. J Interferon Cytokine Res 24:37–41
43.
Bacoyiannis C, Dimopoulos MA, Kalofonos HP et al. (2002) Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials. Oncology 63:130–138PubMed
44.
Negrier S, Caty A, Lesimple T et al. (2000) Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d’Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 18:4009–4015PubMed
45.
Neri B, Cini G, Doni L et al. (2002) Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study. Br J Cancer 87:497–501PubMed
46.
Vaishampayan U, Flaherty L, Du W et al. (2001) Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma. Cancer 92:519–523PubMed
47.
Schwartsmann G, Medina De Cunha F, Silveira LA et al. (1991) Phase II trial of vinblastine plus nifedipine (VN) in patients with advanced renal cell carcinoma (RCC). Brazilian Oncology Trials Group. Ann Oncol 2:443
48.
Gershanovich MM, Moiseyenko VM, Vorobjev AV et al. (1997) High-dose toremifene in advanced renal-cell carcinoma. Cancer Chemother Pharmacol 39:547–551PubMed
49.
Liu JH, Yang MH, Fan FS et al. (2001) Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study. Urology 57:650–654PubMed
50.
Amarto RJ, Perez C, Pagliaro L (2002) Irofulven, a novel inhibitor of DNA synthesis in metastatic renal cell cancer. Invest New Drugs 20:413–417PubMed
51.
Gez E, Rubinov R, Gaitani D et al. (2002) Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996–2000. Cancer 95:1644-1649PubMed
52.
Chaouche M, Pasturaud AL, Kamioner D et al. (2000) Oxaliplatin, 5-fluorouracil, and folinic acid (Folfox) in patients with metastatic renal cell carcinoma: results of a pilot study. Am J Clin Oncol 23:288-289PubMed
Metadaten
Titel
Chemotherapy in metastatic renal cell cancer
verfasst von
Wolfgang Lilleby
Sophie D. Fosså
Publikationsdatum
01.07.2005
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 3/2005
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-004-0469-x

Weitere Artikel der Ausgabe 3/2005

World Journal of Urology 3/2005 Zur Ausgabe

Free Paper

A new technique combining both polypropylene and vaginal wall sling procedures: can it minimize the risk of urethral and vaginal erosion occurring with synthetic materials?

Topic Paper

Novel approaches in the therapy of metastatic renal cell carcinoma

Free Paper

New tined lead electrode in sacral neuromodulation: experience from a multicentre European study

Topic Paper

Surgery for metastatic renal cell cancer

Topic Paper

Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation

Topic Paper

Nonmyeloablative allogeneic stem cell transplantation in metastatic renal cell carcinoma: a new therapeutic option or just a clinical experiment?

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise